Observational study on the usefulness of telemedicine for patients initiating house dust mite sublingual immunotherapy - Observational study on the usefulness of telemedicine for patients initiating house dust mite sublingual immunotherapy

Pauroom, Clinic for Children and Parents0 sites20 target enrollmentFebruary 6, 2024

ConditionsPerennial allergic rhinitis caused by house dust mite

Overview

Phase: N/A
Intervention: Not specified
Conditions: Perennial allergic rhinitis caused by house dust mite
Sponsor: Pauroom, Clinic for Children and Parents
Enrollment: 20
Status: Not Yet Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

February 6, 2024

End Date

December 31, 2025

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Pauroom, Clinic for Children and Parents

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Telemedicine group 1\) Patients who have received or are receiving house dust mite immunotherapy 2\) Patients with a nasal disease (e.g., nasal polyps, deviated septum, hypertrophic rhinitis, etc.) to the extent that it interferes with the evaluation for effectiveness 3\) Patients on anti\-immunoglobulin E (IgE) antibody products, human anti\-human interleukin (IL)\-4/13 receptor monoclonal antibodies, or other antibody products indicated for allergic diseases 4\) Patients with concomitant severe bronchial asthma (in adults) or severe persistent bronchial asthma (in children) 5\) Patients who are lactating, pregnant, or hoping to become pregnant 6\) Patients participating in other clinical researches or clinical trials involving interventions 7\) Patients deemed unsuitable as research subjects by the principal investigator or sub\-investigators Face\-to\-face treatment group Data on patients who do not violate any of the following criteria at the index date will be extracted from the database. However, exclusion criteria 1\) is not applicable. 1\) Patients with a history of telemedicine on the same day as the date of prescription of hyposensitization therapy drugs containing mite allergen extracts (allergen immunotherapy drugs) for house dust mite sublingual immunotherapy on or after the index date 2\) Patients with a concomitant nasal disease (e.g., nasal polyps, deviated septum, hypertrophic rhinitis, etc.) 3\) Patients on IgE antibody products, IL\-4/13 receptor monoclonal antibodies, or other antibody products indicated for allergic diseases 4\) Patients with concomitant severe bronchial asthma (in adults) or severe persistent bronchial asthma (in children) 5\) Patients who are lactating, pregnant, or hoping to become pregnant